Adial Pharmaceuticals (NASDAQ: ADIL)
Pharmaceutical Manufacturing • 
Glen Allen, Virginia, United States • 11-20 Employees
Company overview
| Headquarters | 4870 Sadler Rd, Suite 300, Glen Allen, Virginia 23060, US |
| Phone number | +18044878196 |
| Websites | |
| NAICS | 3254 |
| Keywords | Alcohol Addiction, Drug Addiction, Alcohol Abuse, Drug Abuse |
| Founded | 2010 |
| Employees | 11-20 |
| Socials |
Key Contacts at Adial Pharmaceuticals (NASDAQ: ADIL)
Bankole Johnson
Founder & Cmo, Adial
Osama Adil
Owner
Adial Pharmaceuticals (NASDAQ: ADIL) Email Formats
Adial Pharmaceuticals (NASDAQ: ADIL) uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@adialpharma.com), used 71.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@adialpharma.com | 71.4% |
{first initial}{last name} | jdoe@adialpharma.com | 14.3% |
{first name}.{last name} | john.doe@adialpharma.com | 14.3% |
About Adial Pharmaceuticals (NASDAQ: ADIL)
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
Adial Pharmaceuticals (NASDAQ: ADIL) revenue & valuation
| Annual revenue | $1,368,880 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $4,400,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Adial Pharmaceuticals (NASDAQ: ADIL) has 7 employees across 6 departments.
Departments
Number of employees
Funding Data
Adial Pharmaceuticals (NASDAQ: ADIL) has never raised funding before.
Adial Pharmaceuticals (NASDAQ: ADIL) Tech Stack
Discover the technologies and tools that power Adial Pharmaceuticals (NASDAQ: ADIL)'s digital infrastructure, from frameworks to analytics platforms.
Advertising
Security
CMS
CDN
Advertising
Font scripts
JavaScript libraries
Miscellaneous
Programming languages
Blogs
JavaScript libraries
Analytics
Denmark
Germany
Czechia
Frequently asked questions
4.8
40,000 users
